Scholarly Research Exchange

Scholarly Research Exchange / 2009 / Article

Review Article | Open Access

Volume 2009 |Article ID 938325 | 7 pages | https://doi.org/10.3814/2009/938325

Vasoactive Intestinal Peptide Tumor

Received13 Oct 2008
Accepted18 Feb 2009
Published05 Apr 2009

Abstract

Background and aim. Vasoactive intestinal peptide tumor is a rare neuroendocrine neoplasm which causes voluminous watery diarrhea via hypersecretion of electrolytes and water from the intestinal mucosa through a vasoactive intestinal peptide-mediated, cyclic AMP-dependent mechanism. The acid base imbalance generated by the loss of water and electrolytes leads to severe dehydration and potential renal failure, which can ultimately result in death if left untreated. This paper aims to review the clinical, histological, radiological, and diagnostic features of this disease as well as the therapeutic modalities in treating this condition. Methods. A review of literature was performed using MEDLINE, Pubmed, and Cochrane databases in collection of data using MeSH terms including vasoactive intestinal peptide, VIPoma, and WDHA. Results and conclusion. Vasoactive intestinal peptide tumor is a rare neoplasm associated with significant morbidity and mortality through secretion of water and electrolytes in the gastrointestinal tract. The nonspecific clinical presentation of this neoplasm can pose diagnostic challenges, as these tumors can be easily misdiagnosed as other conditions, ranging from laxative overdose to the presence of a carcinoid secreting tumor. Nevertheless, a number of imaging and laboratory studies can facilitate the correct evaluation and diagnosis of VIPoma. Following proper diagnosis, VIPomas are treated by either medical or surgical modalities depending on the existence and extent of metastasis.

References

  1. J. V. Verner and A. B. Morrison, “Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia,” The American Journal of Medicine, vol. 25, no. 3, pp. 374–380, 1958. View at: Publisher Site | Google Scholar
  2. G. J. Krejs, “VIPoma syndrome,” The American Journal of Medicine, vol. 82, no. 5, pp. 37–48, 1987. View at: Google Scholar
  3. D. Schoevaerdts, L. Favet, D. Zekry, C. C. Sieber, and J. P. Michel, “Vipoma: effective treatment with octreotide in the oldest old,” Journal of the American Geriatrics Society, vol. 49, no. 4, pp. 496–497, 2001. View at: Publisher Site | Google Scholar
  4. I. Drivas, R. Mansberg, and J. M. Roberts, “VIPoma: a rare cause of a pancreatic mass,” Clinical Nuclear Medicine, vol. 29, no. 3, pp. 201–203, 2004. View at: Publisher Site | Google Scholar
  5. M. S. Murphy, A. Sibal, and J. R. Mann, “Persistent diarrhoea and occult vipomas in children,” British Medical Journal, vol. 320, no. 7248, pp. 1524–1526, 2000. View at: Publisher Site | Google Scholar
  6. J. Keller, J. C. Mueller-Wolf, K. Ahmadi-Simab, C. Fibbe, U. Rosien, and P. Layer, “Do elevated plasma Vasoactive Intestinal Polypeptide (VIP) levels cause small intestinal motor disturbances in humans?,” Digestive Diseases and Sciences, vol. 50, no. 2, pp. 276–282, 2005. View at: Publisher Site | Google Scholar
  7. S. Y. Peng, J. T. Li, Y. B. Liu et al., “Diagnosis and treatment of VIPoma in China: (case report and 31 cases review) diagnosis and treatment of VIPoma,” Pancreas, vol. 28, no. 1, pp. 93–97, 2004. View at: Publisher Site | Google Scholar
  8. S. H. Quak, K. Prabhakaran, R. Kwok, and A. P. O'Reilly, “Vasoactive intestinal peptide secreting tumours in children: a case report with literature review,” Australian Paediatric Journal, vol. 24, no. 1, pp. 55–58, 1988. View at: Google Scholar
  9. M. G. Kane and T. M. O'Dorisio, “VIPoma syndrome,” Seminars in Oncology, vol. 14, no. 3, pp. 282–291, 1983. View at: Google Scholar
  10. F. Aspestrand, F. Kolmannskog, and M. Jacobsen, “CT, MR imaging and angiography in pancreatic apudomas,” Acta Radiologica, vol. 34, no. 5, pp. 468–473, 1993. View at: Google Scholar
  11. C. Vick, C. J. Zech, S. Höpfner, T. Waggershauser, and M. Reiser, “Imaging of neuroendocrine tumors of the pancreas,” Radiologe, vol. 43, no. 4, pp. 293–300, 2003. View at: Publisher Site | Google Scholar
  12. R. C. Semelka, C. M. Custodio, N. Cem Balci, and J. T. Woosley, “Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI,” Journal of Magnetic Resonance Imaging, vol. 11, no. 2, pp. 141–148, 2000. View at: Publisher Site | Google Scholar
  13. M. A. Anderson, S. Carpenter, N. W. Thompson, T. T. Nostrant, G. H. Elta, and J. M. Scheiman, “Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas,” American Journal of Gastroenterology, vol. 95, no. 9, pp. 2271–2277, 2000. View at: Publisher Site | Google Scholar
  14. J. C. Ardengh, G. A. de Paulo, and A. P. Ferrari, “EUS-guided FNA in the diagnosis of pancreatic neuroendocrine tumors before surgery,” Gastrointestinal Endoscopy, vol. 60, no. 3, pp. 378–384, 2004. View at: Publisher Site | Google Scholar
  15. H. J. C. Shin, S. Lahoti, and N. Sneige, “Endoscopic ultrasound-guided fine-needle aspiration in 179 cases: the M. D. Anderson cancer center experience,” Cancer, vol. 96, no. 3, pp. 174–180, 2002. View at: Publisher Site | Google Scholar
  16. National Cancer Institute, “Pancreatic tumors: miscellaneous islet cell carcinoma,” July 2006, http://www.cancer.gov/cancertopics/pdq/treatment/isletcell/HealthProfessional/page8. View at: Google Scholar
  17. C. G. Moertel, C. M. Johnson, M. A. McKusick et al., “The management of patients with advanced carcinoid tumors and islet cell carcinomas,” Annals of Internal Medicine, vol. 120, no. 4, pp. 302–309, 1994. View at: Google Scholar
  18. N. L. Kelekis and R. C. Semelka, “MRI of pancreatic tumors,” European Radiology, vol. 7, no. 6, pp. 875–886, 1997. View at: Publisher Site | Google Scholar
  19. I. Virgolini, T. Traub-Weidinger, and C. Decristoforo, “Nuclear medicine in the detection and management of pancreatic islet-cell tumours,” Clinical Endocrinology & Metabolism, vol. 19, no. 2, pp. 213–227, 2005. View at: Publisher Site | Google Scholar
  20. I. Virgolini, A. Kurtaran, M. Leimer et al., “Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy,” Journal of Nuclear Medicine, vol. 39, no. 9, pp. 1575–1579, 1998. View at: Google Scholar
  21. N. Scheffold, R. Arnold, and J. Cyran, “Metastasizing VIPoma of the pancreas: diagnostic aspects and treatment with octreotide (somatostatin analogue),” Deutsche Medizinische Wochenschrift, vol. 120, no. 43, pp. 1463–1467, 1995 (German). View at: Publisher Site | Google Scholar
  22. S. Riestra, A. Suárez, L. Rodrigo et al., “Vipoma of the pancreas. Apropos of a case and review of the literature,” Revista Espanola de Enfermedades Digestivas: Organo Oficial de la Sociedad Espanola de Patologia Digestiva, vol. 77, no. 5, pp. 377–383, 1990. View at: Google Scholar
  23. R. Ram, N. Natanzi, P. Saadat, D. Eliav, and M. S. Vadmal, “Skin metastasis of pancreatic vasoactive intestinal polypeptide tumor: case report and review of the literature,” Archives of Dermatology, vol. 142, no. 7, pp. 946–947, 2006. View at: Publisher Site | Google Scholar
  24. S. J. Moug, E. Leen, P. G. Horgan, and C. W. Imrie, “Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma,” Pancreatology, vol. 6, no. 1-2, pp. 155–159, 2006. View at: Publisher Site | Google Scholar
  25. C. G. Moertel, M. Lefkopoulo, S. Lipsitz, R. G. Hahn, and D. Klaassen, “Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma,” The New England Journal of Medicine, vol. 326, no. 8, pp. 519–523, 1992. View at: Google Scholar
  26. C. Cellier, C. Yaghi, E. Cuillerier et al., “Metastatic jejunal VIPoma: beneficial effect of combination therapy with interferon-α and 5-fluorouracil,” American Journal of Gastroenterology, vol. 95, no. 1, pp. 289–293, 2000. View at: Publisher Site | Google Scholar
  27. B. Eriksson and K. Oberg, “An update of the medical treatment of malignant endocrine pancreatic tumors,” Acta Oncologica, vol. 32, no. 2, pp. 203–208, 1993. View at: Publisher Site | Google Scholar
  28. C. C. Case, K. Wirfel, and R. Vassilopoulou-Sellin, “Vasoactive intestinal polypeptide-secreting tumor (VIPoma) with liver metastases: dramatic and durable symptomatic benefit from hepatic artery embolization, a case report,” Medical Oncology, vol. 19, no. 3, pp. 181–187, 2002. View at: Publisher Site | Google Scholar
  29. S. Ito, M. Kasturagi, H. Otsuji et al., “Transcatheter embolization of metastatic liver VIPoma: report of a case,” Japanese Journal of Clinical Radiology, vol. 32, no. 10, pp. 1169–1172, 1987. View at: Google Scholar
  30. M. T. Tauber, A. G. Harris, and P. Rochiccioli, “Clinical use of the long acting somatostatin analogue octreotide in pediatrics,” European Journal of Pediatrics, vol. 153, no. 5, pp. 304–310, 1994. View at: Publisher Site | Google Scholar
  31. K. D. Buchanan, “Effects of sandostatin on neuroendocrine tumours of the gastrointestinal system,” Recent Results in Cancer Research, vol. 129, pp. 45–55, 1993. View at: Google Scholar
  32. S. R. Bloom, “Vipoma, glucagonoma and the role of Sandostatin,” NATNews, vol. 26, no. 7, p. 15, 1989. View at: Google Scholar
  33. A. W. Kirkpatrick, S. S. Hanna, and B. A. J. Skinner, “Surgical treatment of pancreatic cholera: a case report,” Canadian Journal of Surgery, vol. 39, no. 2, pp. 155–158, 1996. View at: Google Scholar
  34. B. Brichard, R. Fiasse, J. P. Buts et al., “Vipoma in an adolescent: treatment with a delayed-action somatostatin analog, octreotide or SMS 201-995, and surgical removal,” Acta Gastroenterologica Belgica, vol. 53, no. 2, pp. 188–197, 1990. View at: Google Scholar

Copyright © 2009 Naveed Natanzi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

206 Views | 0 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.